In that study, we showed that systemic administration of TfR-siRNA LNP resulted in tumor-targeted selective delivery of therapeutic siRNA to subcutaneous and experimental lung metastasis resulting in effective tumor suppression and prolonged animal survival. Here, TFRC is linked to neoplasm.